SCHEMBL5621065

SCHEMBL5621065

CCNc1nc(C)c(-c2ccnc(Nc3ccc(OC)nc3)n2)s1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 17/20 0.69
AURKA O14965 11/20 0.69
CDK9 P50750 11/20 0.69
AURKB Q96GD4 10/20 0.69
CDK7 P50613 9/20 0.69
CDK1 P06493 8/20 0.69
CDK4 P11802 13/20 0.60
FLT3 P36888 4/20 0.59
WEE1 P30291 3/20 0.59
ALK Q9UM73 3/20 0.59
CHEK1 O14757 2/20 0.56
DAPK3 O43293 2/20 0.56
JAK2 O60674 2/20 0.56
PRKD3 O94806 2/20 0.56
PAK4 O96013 2/20 0.56
ABL1 P00519 2/20 0.56
FYN P06241 2/20 0.56
CSF1R P07333 2/20 0.56
RET P07949 2/20 0.56
IGF1R P08069 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5621875 0.89 CDK2 (0.55) CDK2AURKACDK9AURKBCDK7
SCHEMBL5620027 0.89 CDK2 (0.67) CDK2AURKACDK9AURKBCDK7
SCHEMBL5785189 0.85 CDK2 (0.52) CDK2AURKACDK9AURKBCDK7
SCHEMBL4171151 0.85 CDK2 (0.78) CDK2AURKACDK9AURKBCDK7
SCHEMBL5620620 0.85 CDK2 (0.69) CDK2AURKACDK9AURKBCDK7
SCHEMBL6156585 0.84 CDK2 (0.71) CDK2AURKACDK9AURKBCDK7
SCHEMBL2289132 0.84 CDK2 (0.51) CDK2AURKACDK9AURKBCDK7
SCHEMBL5781649 0.83 CDK2 (0.67) CDK2AURKACDK9AURKBCDK7
SCHEMBL4165787 0.83 CDK2 (0.77) CDK2AURKACDK9AURKBCDK7
SCHEMBL4803155 0.83 CDK2 (0.71) CDK2AURKACDK9AURKBCDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007500178-A 2007-01-11 JP claimed
US-20060241297-A1 Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors CYCLACEL LIMITED (GB) 2006-10-26 US claimed
EP-1648887-A1 PYRIDINYLAMINO-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS Cyclacel Limited (GB) 2006-04-26 EP claimed
WO-2005012298-A1 PYRIDINYLAMINO-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 WO claimed
US-20060241297-A1 Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors CYCLACEL LIMITED (GB) 2006-10-26 US disclosed
EP-1648887-A1 PYRIDINYLAMINO-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS Cyclacel Limited (GB) 2006-04-26 EP disclosed
WO-2005012298-A1 PYRIDINYLAMINO-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 WO disclosed
WO-2005012298-A1 PYRIDINYLAMINO-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241297-A1 Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors FRK, CNKSR1, TYK2 CDK2 8/4885AURKA 611/4885CDK9 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.